180 Life Sciences (ATNF)
(Delayed Data from NSDQ)
$1.86 USD
-0.11 (-5.58%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $1.86 0.00 (0.00%) 4:44 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for 180 Life Sciences Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 13 | 18 | 16 | 6 | 1 |
Income After Depreciation & Amortization | -13 | -18 | -16 | -6 | -1 |
Non-Operating Income | -9 | -22 | -5 | -4 | 1 |
Interest Expense | 0 | 0 | 0 | 1 | 0 |
Pretax Income | -22 | -40 | -20 | -11 | 0 |
Income Taxes | -2 | -1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -20 | -39 | -20 | -11 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -20 | -39 | -20 | -11 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -11 | 18 | -13 | -5 | -1 |
Depreciation & Amortization (Cash Flow) | 2 | 36 | 3 | 0 | 0 |
Income After Depreciation & Amortization | -13 | -18 | -16 | -6 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.38 | 0.10 | 0.08 | NA | NA |
Diluted EPS Before Non-Recurring Items | -28.68 | -198.67 | -247.15 | NA | NA |
Diluted Net EPS (GAAP) | -52.59 | -387.45 | -247.15 | -250.95 | -7.60 |
Fiscal Year end for 180 Life Sciences Corp falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 1.84 | 2.10 | 1.45 | 3.53 | 3.68 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.84 | -2.10 | -1.45 | -3.53 | -3.68 |
Non-Operating Income | 1.87 | 1.04 | 0.23 | -9.06 | 0.01 |
Interest Expense | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
Pretax Income | 0.01 | -1.07 | -1.23 | -12.61 | -3.68 |
Income Taxes | 0.00 | 0.00 | 0.00 | -2.35 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 0.01 | -1.07 | -1.23 | -10.27 | -3.68 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 0.01 | -1.07 | -1.23 | -10.27 | -3.68 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 0.92 | 0.64 | NA | 0.42 | 0.28 |
Diluted EPS Before Non-Recurring Items | 0.01 | -1.68 | NA | -2.85 | -13.31 |
Diluted Net EPS (GAAP) | 0.01 | -1.68 | 9.39 | -24.52 | -13.31 |